Welcome to our dedicated page for Optimizerx SEC filings (Ticker: OPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for revenue drivers behind OptimizeRx’s digital health messaging platform or tracking when executives buy shares? This SEC filings hub surfaces the answers investors usually dig for in hundreds of pages. From growth in EHR integrations to pharma-sponsor concentration risk, every disclosure is here and searchable.
Use Stock Titan’s AI to move quickly:
- Instant summaries turn the OptimizeRx annual report 10-K simplified into an easy-to-scan brief that flags platform usage metrics and data-security risk factors.
- Redline comparisons highlight quarter-over-quarter changes inside the OptimizeRx quarterly earnings report 10-Q filing, letting you follow revenue trajectory without crunching spreadsheets.
- Real-time alerts stream OptimizeRx Form 4 insider transactions so you know about executive stock moves the moment they hit EDGAR.
Typical questions are answered as you browse: “How did OptimizeRx finance its last acquisition?”—see the OptimizeRx 8-K material events explained. “What are management’s option grants?”—open the OptimizeRx proxy statement executive compensation. Want to watch director trades? Check OptimizeRx insider trading Form 4 transactions and drill into each filing with AI commentary. Whether you need an OptimizeRx earnings report filing analysis before the call or prefer understanding OptimizeRx SEC documents with AI after hours, our platform covers every filing type with timely updates and plain-language insight.
OptimizeRx Corporation (OPRX) reported stronger quarterly results driven by growth in DTC and DAAP offerings. Net revenue rose 55% year-over-year to $29,195 (in thousands) for the three months ended June 30, 2025 and increased 33% to $51,123 for the six months ended June 30, 2025, reflecting higher direct-to-consumer and AI-driven audience activation sales. Gross margin improved to 63.8% for the quarter as cost-of-revenue as a percentage of sales declined to ~36% due to solution and channel mix.
The company delivered GAAP net income of $1,532 for Q2 2025 versus a loss of $4,008 in Q2 2024, produced $8,425 of operating cash flow in the six months, and reduced long-term debt net to $25,127 with a Term Loan outstanding of $29,290. Management remains covenant-compliant but carries significant Term Loan interest (13.1% rate reported) and future principal due in 2027. A previously identified material weakness in controls over third-party data is being remediated.
OptimizeRx Corporation (OPRX) filed an 8-K on June 24, 2025 to disclose a governance change. Effective June 20, 2025, the Board of Directors expanded from five to six members and appointed CEO Stephen Silvestro to fill the new seat. Silvestro will serve until the 2026 annual meeting, subject to earlier resignation or removal. No other executive departures, financial data, or strategic transactions were reported. The company furnished a related press release as Exhibit 99.1; the information in Item 7.01 is deemed “furnished,” not “filed,” under the Exchange Act.
Aside from this board adjustment, the 8-K contains no updates on earnings, guidance, or operations. Therefore, the filing is primarily informational and unlikely to have a material impact on valuation or near-term cash flows.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
